Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.
Polyaspartic acid (PAA) ameliorates experimental gentamicin nephrotoxicity despite marked accumulation of gentamicin in the renal cortex. The experiments described here probe the extent of PAA's nephroprotective action when increasing doses of gentamicin, in excess of an established nephrotoxic dose (40 mg/kg of body weight per day), are administered. After 10 days, virtually complete nephroprotection was conferred by PAA coadministered to animals receiving three times the nephrotoxic dose (120 mg/kg/day) of gentamicin.
Swan
S K
SK
Division of Nephrology, Hypertension, and Clinical Pharmacology, Oregon Health Sciences, Portland 92701.
Gilbert
D N
DN
Kohlhepp
S J
SJ
Kohnen
P W
PW
Bennett
W M
WM
D000818:Animals; D003404:Creatinine / Q000097:blood; D005839:Gentamicins / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000633:toxicity; D007279:Injections, Subcutaneous; D007668:Kidney / Q000473:pathology; D007672:Kidney Cortex / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344
D005839:Gentamicins; D010455:Peptides; C017645:polyaspartate; D003404:Creatinine